Latest Industry Insights

We recently spoke to Alif Saleh, CEO of Scipher Medicine to learn how RNA data from a patient’s blood sample can be used to determine the underlying molecular processes driving a disease, and establish how well a patient will respond to a particular therapy.

Cities often don't work very well. Bins don't get collected. Traffic queues are long. Shops run out of goods. The Russian team behind Airalab think that AI can help streamline cities and the economy more widely. Their Robonomics platform aims to make it easier to bring automated, intelligent technology into the economy. With Smart City projects already on the go, from Dubai to Milton Keynes, we spoke to Airalab's Aleksandr Kapitonov to find out more.

Assay sensitivity and specificity continues to be a challenge in measuring hormones at low concentrations. Tandem mass spectrometry offers significant advantages - particularly in a clinical setting, where speed and sensitivity are required. Following SCIEX' launch of a new tandem mass spectrometry system, we spoke with Michael Jarvis, Product Manager at SCIEX, to find out more.

We recently spoke to Karoly Nikolich, chairman and chief executive officer of Alkahest, a clinical-stage biotechnology company, to learn more about their approach to developing therapeutics for both neurodegenerative and age-related diseases.

OmniTier Inc.’s new bioinformatics platform, CompStorTM Novos, takes a de novo assembly-based variant calling approach to the challenge of whole genome sequencing. We caught up with Jon Coker, Omnitier’s CTO, to discuss how this approach matches up to rival techniques, and how high-performance computing approaches like Omnitier’s hope to bring personalized medicine a step closer and boost biology in coming years.

While immunotherapy holds great promise for cancer treatment, challenges persist around limited response rate and severe immune-related adverse events. We caught up with Dr. Georg Lautscham, CEO of Protagen, to find out how the prediction of immunotherapy response can be improved for people with urothelial cancer.

High content screeening (HCS) has become a staple tool for scientists trying to find out how molecules alter our cells' biological systems. The huge volume of data that HCS produces is both its strength and weakness. As assays become more complex, companies like Genedata are turning to AI-based approaches to help streamline HCS analysis. I spoke to Genedata's Head of Science, Dr. Stephan Steigele, to find out more.

Recent technology advancements have enabled the opportunity to increase the efficiency, efficacy and safety of gene and cell-based medicines for a multitude of genetic disorders. To date, a major challenge facing the field has been the ability to deliver therapeutic genes to affected cell types. In this blog, Sarah Haecker Meeks and Michael Roberts from Synpromics outline the ways in which gene medicines can be optimized to overcome this barrier.

Life science businesses are facing growing demand to keep pace in an era of fast-evolving technology. By recognizing the potential challenges, a growing number of companies are leveraging the resources and creativity of their suppliers. We took a look at the landscape of optofluidics R&D.

We recently spoke to Alexis Peyroles, CEO at OSE Immunotherapeutics to hear more about the findings of their recent study, describing, for the first time ever, the in vivo MOA of interleukin 7 receptor alpha (IL-7Rα) monoclonal antibodies, suggesting therapeutic efficacy in controlling chronic inflammation.